Cisplatin is a very common chemotherapeutic agent used in the treatment of gynecologic malignancies, including cervical, ovarian, and endometrial cancers. Bradycardia is a rare, though potentially severe, side effect of this medication. Here we present the case of a young woman with ovarian cancer who demonstrated significant short-lived cardiotoxicity associated with cisplatin treatment.
YavasOAytemirKCelikI. The prevalence of silent arryhthmia in patients receiving cisplatin-based chemotherapy. Turkish J Cancer2008; 38: 12–15.
4.
HomesleyHBundyBNHurteauJ. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol1999; 72: 131–137.
ShimuzuWAntzelevitchC. Cellular bases for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. J Electrocardiol1999; 32(Suppl): 177–184.
9.
IsbisterGPageC. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol2013; 76: 48–57.
